Rapport Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Rapport Therapeutics, Inc. (RAPP) reported Increase (Decrease) in Accounts Payable of -$1.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$3.68M, a 456.84% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.31M, a 1145.95% increase year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.18M, a 81.79% increase year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$179.00K, a 489.13% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $2.21M.
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$346.00K, a 140.42% decline from fiscal 2023.
- Rapport Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $856.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.37M 10-Q · filed 2026-08-05 | -$196.00K derived: sum of 3 quarters · filed 2026-08-05 | -$375.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.31M 10-Q · filed 2026-05-07 | $3.48M derived: sum of 2 quarters · filed 2026-05-07 | $3.30M derived: sum of 3 quarters · filed 2026-05-07 | $4.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $999.00K derived: sum of 2 quarters · filed 2026-03-10 | $2.03M derived: sum of 3 quarters · filed 2026-08-05 | $2.21M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $852.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.04M 10-Q · filed 2025-11-06 | $1.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.22M 10-Q · filed 2026-08-05 | $1.86M derived: sum of 3 quarters · filed 2026-08-05 | $1.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $185.00K 10-Q · filed 2026-05-07 | $833.00K derived: sum of 2 quarters · filed 2026-05-07 | $879.00K derived: sum of 3 quarters · filed 2026-05-07 | $973.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $648.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $694.00K derived: sum of 2 quarters · filed 2026-03-10 | $788.00K derived: sum of 3 quarters · filed 2026-03-10 | -$346.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $140.00K derived: sum of 2 quarters · filed 2025-11-06 | -$994.00K 10-Q · filed 2025-11-06 | -$269.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.04M 10-Q · filed 2025-08-07 | -$315.00K derived: sum of 3 quarters · filed 2025-08-07 | $318.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.13M 10-Q · filed 2025-05-08 | -$409.00K derived: sum of 2 quarters · filed 2025-05-08 | $224.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $725.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.36M derived: sum of 2 quarters · filed 2025-03-11 | $856.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $633.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $131.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$502.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |